Zydus Cadila gets USFDA nod for anti-cholesterol drug
New Delhi: Drug firm Zydus Cadila has received approval from the US health regulator to market an anti-cholesterol drug, Cholestyramine, in the American market.
The company has received final approval from the US Food and Drug Administration (USFDA) to market the product, Zydus Cadila said in a statement.
The US is the world's largest drug market and approvals to sell generic medicines there provide companies opportunities to increase their revenue.
Cholestyramine is indicated for the reduction of elevated serum cholesterol.
The product would be manufactured at the company's facility at Baddi in Himachal Pradesh.
The Ahmedabad-based group has now more than 110 approvals from the USFDA.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd